• Biotech organizations are under increasing pressure to scale.
• Yet many remain stuck in siloed planning, making it difficult to scale across lab, manufacturing, and commercial operations.
• What works in early-stage development often breaks down as volumes increase, modalities diversify, and patient-centric models become the norm.
• This session explores why scaling planning in biotech is uniquely complex, starting in the lab and extending all the way to the patient.
• We will dive into common planning challenges across biotech operations, including fragmented data, manual processes, and disconnected systems that limit visibility and agility.
• We will also look at concrete use cases in areas such as Cell and Gene Therapies and other vein to vein models, where planning must account for single-patient batches, strict chain-of-custody requirements, and extreme sensitivity to delays.